Reumatizam, Vol. 57 No. 2, 2010.
Izlaganje sa skupa
Interstitial lung disease (ILD) in systemic sclerosis (SSc)
Srđan Novak
; Odjel za reumatologiju i kliničku imunologiju, Klinika za internu medicinu, Klinički bolnički centar Rijeka, Rijeka, Hrvatska
Sažetak
Intersitial lung disease is a frequent complication of systemic sclerosis that often has a poor pognosis and together with pulmonary arterial hypertension are the most common cause of death in scleroderma patients. For detection and evaluation of interstitial lung disease, high-resolution CT and pulmorary functional tests are pivotal. The decision about whether to start treatment is often the most difficult challenge. Patients with short duration of systemic disease with recent deterioration in DCO are the candidates for immunosupressive therapy. Best current initial treatment is intravenous monthly cyclophosphamide together with low-dose oral glucocorticoids although azathioprine and mycophenolate mofetil are also widelly used.
Ključne riječi
cyclophosphamide; immunosuppressive therapy; intersitial lung disease; systemic sclerosis
Hrčak ID:
124633
URI
Datum izdavanja:
14.10.2010.
Posjeta: 1.692 *